WO2006021968A1 - PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE - Google Patents

PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE Download PDF

Info

Publication number
WO2006021968A1
WO2006021968A1 PCT/IN2004/000264 IN2004000264W WO2006021968A1 WO 2006021968 A1 WO2006021968 A1 WO 2006021968A1 IN 2004000264 W IN2004000264 W IN 2004000264W WO 2006021968 A1 WO2006021968 A1 WO 2006021968A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
oxo
methyl
oxopropyl
compound
Prior art date
Application number
PCT/IN2004/000264
Other languages
French (fr)
Inventor
Joy Mathew
Tom Thomas Puthiaprampil
Ravindra Chandrappa
Sambasivam Ganesh
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Priority to JP2007529139A priority Critical patent/JP2008510797A/en
Priority to CA002578721A priority patent/CA2578721A1/en
Priority to US11/574,296 priority patent/US20070249865A1/en
Priority to PCT/IN2004/000264 priority patent/WO2006021968A1/en
Priority to EP04770699A priority patent/EP1784384A4/en
Publication of WO2006021968A1 publication Critical patent/WO2006021968A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • Atorvastatin known as "4-Fluoro- ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide " (Formula I) was disclosed in patents US 5,124,482.
  • the compound of 5 Formula I can be further processed to get atorvastatin and the purity of the final product atorvastatin is highly dependent on the purity of the compound of Formula I.
  • the prior art processes suffer from a major disadvantage of generation of impurities like ⁇ -[2-methyI-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide and difluoro- ⁇ -[2-methyl-l-oxopropyI] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide.
  • the reaction need to be carried out under controlled conditions (e.g.: highly anhydrous conditions) to l o avoid formation of the impurities.
  • the prior art also mentions that presence water, even in trace amounts, result in the impurities.
  • desfluro atorvastatin is one of the known impurities in atorvastatin, which arises due to the presence of like ⁇ -[2-methyI-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide in 4-Fluoro- ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene
  • the instant invention provides a solution to the above-mentioned problems and provides a more preferred alternative to the prior art processes.
  • the objective of the present invention is to provide an alternative, industrially scalable process for the synthesis of substantially pure compound of 5 Formula I which can be used to get substantially pure atorvastatin.
  • the present invention details a novel process for the preparation of substantially pure 4-Fluoro- ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide 0 (Formula I).
  • the base is sodium carbonate and or a mixture of sodium carbonate and diisopropyl ethylamine.
  • Form I 4-Fluoro- ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide
  • HMG Co-A reductase inhibitors are useful as inhibitors of the enzyme
  • HMG CoA reductase 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase) and are thus useful as hypolipidemic or hypocholesterolemic agents.
  • the process of the present invention in its first aspect is a new, improved, economical, commercially feasible and clean method for preparing intermediate used for the preparation of HMG CoA reductase inhibitors.
  • the instant invention discloses a process for the preparation of substantially pure compound of formula I
  • Substantially pure compound of Formula I containing less than 0.2% of ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide.
  • Substantially pure compound of Formula I containing less than 0.1% of difluoro ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide.
  • the present invention has following advantages over known method:
  • the substantially pure compound of Formula I can be further processed to get substantially pure atorvastatin, almost free of impurities like desfloro atorvastatin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel process for the preparation of substantially pure 4-Fluoro-α-[2-methyl-1-oxopropyl]Ϝ-oxo-N-β-diphenylbenzene butane amide.

Description

5 TITLE OF THE INVENTION
PROCESS FOR PREPARATION OF
4-FLUORO-α-[2-METHYL-l-OXOPROPYL]γ-OXO-N-β-DIPHENYLBENZE NE BUTANE AMIDE
TECHNICAL FIELD OF THE INVENTION l o The present invention relates to a process for preparing
4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide (Formula I), a key intermediate useful for synthesis of HMG-CoA enzyme inhibitor, atorvastatin.
BACKGROUND OF THE INVENTION
15 US 5,124,482 and US 5,216,174 disclose manufacture and use of
4~Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzenebutane amide for preparation of Atorvastatin was first disclosed in US patent 4,681,893. Atorvastatin calcium was claimed in US patent 5,273,995.
Many patent application(s)/publications disclose process for the 0 preparation of Atorvastatin calcium viz. US 5,003,080, US 5,169,857, WO 01/85702, US 5,354,772, EP 0 304 063
A key intermediate in the process for the synthesis of Atorvastatin known as "4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide " (Formula I) was disclosed in patents US 5,124,482. The compound of 5 Formula I can be further processed to get atorvastatin and the purity of the final product atorvastatin is highly dependent on the purity of the compound of Formula I.
Processes for the preparation of 4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide 0 are disclosed in the patent(s)/application(s) viz. US 5,216,174. A process for the preparation of compound of Formula I is also disclosed in a research article (J. Labelled Cpd. Radiopharm. 42, 121-127, 1999) where it is mentioned that presence of trace amounts of water during the synthesis of compound of Formula I led to the formation and impurity namely "desfluro derivative of 5 compound of Formula I". 5 The prior art processes suffer from a major disadvantage of generation of impurities like α-[2-methyI-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide and difluoro-α-[2-methyl-l-oxopropyI]γ-oxo-N-β-diphenylbenzene butane amide. According to the prior art literature, the reaction need to be carried out under controlled conditions (e.g.: highly anhydrous conditions) to l o avoid formation of the impurities. The prior art also mentions that presence water, even in trace amounts, result in the impurities. In fact desfluro atorvastatin is one of the known impurities in atorvastatin, which arises due to the presence of like α-[2-methyI-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide in 4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene
15 butane amide, used for the manufacture of atorvastatin.
Therefore, there is a need to find alternative process, which can be used, for the preparation of
4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide which does not lead to the formation of these impurities and does not require the 0 controlled conditions to be maintained during the synthesis.
The instant invention provides a solution to the above-mentioned problems and provides a more preferred alternative to the prior art processes.
The objective of the present invention is to provide an alternative, industrially scalable process for the synthesis of substantially pure compound of 5 Formula I which can be used to get substantially pure atorvastatin. SUMMARY OF THE INVENTION
The present invention details a novel process for the preparation of substantially pure 4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide 0 (Formula I).
Figure imgf000004_0001
Formula I by reacting a compound of formula II
Figure imgf000005_0001
Formula II with a compound of formula III
Figure imgf000005_0002
Formula III
in presence of a base. Preferably the base is sodium carbonate and or a mixture of sodium carbonate and diisopropyl ethylamine.
DETAILED DESCRIPTION OF THE INVENTION
4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide (Formula I) is an important intermediate for the preparation of many drug molecules especially, HMG Co-A reductase inhibitors. The HMG Co-A reductase inhibitors are useful as inhibitors of the enzyme
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase) and are thus useful as hypolipidemic or hypocholesterolemic agents.
The process of the present invention in its first aspect is a new, improved, economical, commercially feasible and clean method for preparing intermediate used for the preparation of HMG CoA reductase inhibitors.
The instant invention discloses a process for the preparation of substantially pure compound of formula I
Figure imgf000006_0001
Formula I comprising of reacting a compound of formula II
Figure imgf000006_0002
Formula II i o with a compound of formula III
Figure imgf000006_0003
Formula III
in presence of a base.
The process where the base selected from sodium carbonate, potassium 15 carbonate, cesium carbonate diisopropyl ethyl amine, triethyl amine or a suitable mixture of two or more these.
The process where the compound of Formula I is further processed to get substantially pure atorvastatin.
0 Substantially pure compound of Formula I,
Figure imgf000007_0001
Formula I
Substantially pure compound of Formula I, containing less than 0.2% of α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide.
Substantially pure compound of Formula I, containing less than 0.1% of difluoro α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide. The present invention has following advantages over known method:
1. Clean process
2. Economic.
3. Industrially scalable. 4. The reagents used are non-hazarous, easily available and economic.
5. Yields substantially pure product, almost free of impurities like α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide.
6. The substantially pure compound of Formula I can be further processed to get substantially pure atorvastatin, almost free of impurities like desfloro atorvastatin.
The following non-limiting examples illustrate the inventors' preferred method for preparing the compounds of the invention.
EXAMPLES
Example 1 Preparation of
4-Fluoro-α-[2-methyl-l-oxopropyI]γ-oxo-N-β-dlphenyIbenzene butane amide:
To a solution of l-(4-Fluoro-phenyl)-2-phenyl-ethanone (1.5g) in DMF (20 ml) sodium carbonate (2.5 g) was added and stirred for 15 minutes. 2-Bromo-4-methyl-3-oxo-pentanoic acid phenylamide (2 g) was added to the reaction mixture and stirred for 18 h. The reaction mixture was further stirred at about 9O0C for 5 hours. After cooling the reaction mixture to room temperature water (100 ml) was added and extracted the mixture with ethyl acetate (2 x 20 ml). The combined organic layer was washed with water and brine and concentrated. The residue was dissolved in hot isopropyl alcohol (15 ml) and cooled to room temperature. The product was filtered and dried. Yield: 1.5 g. The product was analyzed by HPLC and found that content of α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide (desfluro derivative of compound of formula I) was 0.01% Example 2 Preparation of
4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide:
To a suspension of sodium carbonate (5 g) and diisopropyl ethylamine (16 ml) in DMF (100 ml), l-(4-Fluoro-phenyl)-2-phenyl-ethanone (10 g) was added and stirred for 30 minutes. Further bromo-4-methyl-3-oxo-pentanoic acid phenylamide (13.5 g) was added and stirred at room temperature for 18 hours. Subsequently diisopropyl ethylamine (8 ml) and sodium carbonate (2.5 g) were added and stirred for 10 minutes. Further bromo-4-methyl-3-oxo-pentanoic acid phenylamide (3.3 g) was added and stirred at room temperature for 5 hours. The reaction mixture was refluxed at 90-95° C for 6 hours. After cooling the reaction mixture to room temperature, water (200 ml) was added and the contents were extracted with ethyl acetate (250 ml). The organic layer was washed with water and concentrated. The residue was re-crystallized from isopropyl alcohol to yield 4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide.
Yield: 12g
The product was analyzed by HPLC and found that content of α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide (desfluro derivative of compound of formula I) was 0.05%.

Claims

5 We claim:
1. A process for the preparation of substantially pure compound of formula I
Figure imgf000009_0001
Formula I l o comprising of reacting a compound of formula II
Figure imgf000009_0002
Formula II with a compound of formula III
Figure imgf000009_0003
15 Formula III
in presence of a base.
2. A process of claim 1, wherein the base selected from sodium carbonate, potassium carbonate, cesium carbonate diisopropyl ethyl amine, triethyl amine or a suitable mixture of two or more these. 0
3. A process of claim 1, wherein the compound of Formula I is further processed to get substantially pure atorvastatin.
4. Substantially pure compound of Formula I,
Figure imgf000010_0001
5. Substantially pure compound of claim 4, containing less than 0.2% of α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide.
6. Substantially pure compound of claim 4, containing less than 0.1% of difluoro α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide.
PCT/IN2004/000264 2004-08-26 2004-08-26 PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE WO2006021968A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007529139A JP2008510797A (en) 2004-08-26 2004-08-26 Process for producing 4-fluoro-α- [2-methyl-1-oxopropyl] γ-oxo-N-β-diphenylbenzenebutanamide
CA002578721A CA2578721A1 (en) 2004-08-26 2004-08-26 Process for preparation of 4-fluoro-.alpha.-[2-methyl-1-oxopropyl].gamma.-oxo-n-.beta.-diphenylbenzene butane amide
US11/574,296 US20070249865A1 (en) 2004-08-26 2004-08-26 Process for Preparation of 4-Fluoro-Alpha-[2-Methyl-1-Oxopropyl]-Gamma-Oxo-N-Beta- Diphenylbenzene Butane Amide
PCT/IN2004/000264 WO2006021968A1 (en) 2004-08-26 2004-08-26 PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE
EP04770699A EP1784384A4 (en) 2004-08-26 2004-08-26 Process for preparation of 4-fluoro-alpha-[2-methyl-1-oxopropyl]gamma-oxo-n-beta-diphenylbenzene butane amide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000264 WO2006021968A1 (en) 2004-08-26 2004-08-26 PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE

Publications (1)

Publication Number Publication Date
WO2006021968A1 true WO2006021968A1 (en) 2006-03-02

Family

ID=35967198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000264 WO2006021968A1 (en) 2004-08-26 2004-08-26 PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE

Country Status (5)

Country Link
US (1) US20070249865A1 (en)
EP (1) EP1784384A4 (en)
JP (1) JP2008510797A (en)
CA (1) CA2578721A1 (en)
WO (1) WO2006021968A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872154B2 (en) 2008-05-29 2011-01-18 Arch Pharmalabs Limited Method for the preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-y-oxo-n-β-diphenylbenzenebutanamide and products therefrom

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114195670B (en) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 Refining method of atorvastatin mother nucleus M4

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
WO2003004457A2 (en) * 2001-07-04 2003-01-16 Ciba Specialty Chemicals Holding Inc. Preparation process for atorvastatin and intermediates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
CN1181049C (en) * 2000-12-08 2004-12-22 中国科学院上海有机化学研究所 Alpha-alkylacyl-beta-substituted benzoyl-beta-phenylpropionyl aniline and its synthesis and use
JP2006527164A (en) * 2003-06-09 2006-11-30 バイオコン リミテッド Novel halogen-substituted active methylene compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
WO2003004457A2 (en) * 2001-07-04 2003-01-16 Ciba Specialty Chemicals Holding Inc. Preparation process for atorvastatin and intermediates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1784384A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872154B2 (en) 2008-05-29 2011-01-18 Arch Pharmalabs Limited Method for the preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-y-oxo-n-β-diphenylbenzenebutanamide and products therefrom
US8163959B2 (en) 2008-05-29 2012-04-24 Arch Pharmalabs Limited Method for the preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-γ-oxo-N-β-diphenylbenzenebutanamide and products therefrom

Also Published As

Publication number Publication date
US20070249865A1 (en) 2007-10-25
EP1784384A1 (en) 2007-05-16
JP2008510797A (en) 2008-04-10
CA2578721A1 (en) 2006-03-02
EP1784384A4 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
US20070185337A1 (en) Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidine acetamide
CZ285554B6 (en) Process for preparing trans-6-[2-(substituted pyrrol-1-yl)alkyl]-pyran-2-one
WO2012059941A1 (en) Process for preparation of sunitinib malate and salts thereof
KR20080020613A (en) A process for the dynamic resolution of (substituted) (r)- or (s)-mandelic acid
US20060194867A1 (en) Process for the preparation of atorvastatin and intermediates
JP3473976B2 (en) Method for producing alanylglutamine
US7615647B2 (en) Process for producing atorvastatin hemicalcium
KR102255357B1 (en) A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
WO2006021968A1 (en) PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE
WO2008096373A2 (en) Process for synthesizing highly pure nateglinide polymorphs
WO2007052296A2 (en) A process of preparing amorphous atorvastatin calcium
US5808088A (en) Preparation of mibefradil via an acetamide anion
KR101304640B1 (en) Novel n-methylbenzylamine salt of rosuvastatin and process for the preparation thereof
JPH08169878A (en) Production of optically active pyrrolidine having high enantiomer purity
US7265223B2 (en) Intermediate compounds for the preparation of mirtazapine and production methods thereof
SK614690A3 (en) 5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indole derivatives, preparation method thereof and pharmaceutical compositions containing them
HU231050B1 (en) Process for the preparation of a pharmaceutical active ingredient
ES2323366T3 (en) NEW PROCEDURE FOR THE STEREOSELECTIVE REDUCTION OF BETA-CETOSTERS.
CN110835319B (en) Synthesis method of benazepril intermediate and benazepril hydrochloride
US20100174073A1 (en) Process for the preparation of alfuzosin and salts thereof
WO1998035934A1 (en) η-OXO-HOMOPHENYLALANINE DERIVATIVES AND PROCESS FOR PRODUCING HOMOPHENYLALANINE DERIVATIVES BY REDUCING THE SAME
WO2007086559A1 (en) Method for producing tetrahydropyran compound
JPH11199562A (en) 1-(3-alkanoylthio-2-alkylpropanoyl)-propylphenyl-alanine
JP2000212151A (en) Production of lower alkyl ester of (r)-4-cyano-3- hydroxybutyric acid
JPWO2003095446A1 (en) Process for producing 1- (4-pyridyl) -4-piperidone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 755/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2578721

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004770699

Country of ref document: EP

Ref document number: 11574296

Country of ref document: US

Ref document number: 2007529139

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2004770699

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11574296

Country of ref document: US